Back

Pulmonary hypertension experts discuss individualizing therapy for pulmonary arterial hypertension (PAH), from guideline-based risk stratification and upfront combination therapy to escalation, switching, and parenteral transitions, with practical guidance on right heart assessment, adherence, emerging therapies, and partnering with community clinicians.

Individualizing PAH Therapy in an Evolving Treatment Landscape

Episodes

Specialty:

All

Year:

All

EP. 1: PAH Risk Assessment: Why Reaching Low Risk Matters for Patients

ByVallerie McLaughlin, MD,Richard Channick, MD,Anjali Vaidya, MD, FACC, FASE, FACP,Nick H. Kim, MD

October 27th 2026

Intermediate- and high-risk status signals a struggling right ventricle and a prognosis the panel considers unacceptable. They argue for treating risk assessment as a routine vital sign while weighing what patients say they want from therapy.

EP. 2: PAH Care Teams, Unmet Needs, and the Four Treatment Pathways

ByVallerie McLaughlin, MD,Richard Channick, MD,Anjali Vaidya, MD, FACC, FASE, FACP,Nick H. Kim, MD

October 27th 2026

PAH rarely belongs to a single specialty. The panel describes the team-based model behind effective care and reviews how four complementary treatment pathways now give clinicians a broad toolbox.

Individualizing PAH Therapy in an Evolving Treatment Landscape

Episodes

EP. 1: PAH Risk Assessment: Why Reaching Low Risk Matters for Patients

EP. 2: PAH Care Teams, Unmet Needs, and the Four Treatment Pathways

Trending on HCPLive

eGFR Underestimates CKD in Patients with Cancer, Study Finds

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER

VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH

Kidney Compass: New FIND-CKD Finerenone Data From ASN Kidney Week 2026